Cutaneous complications are increasingly recognized among children and adolescents with the use of adhesive-based medical technologies. A cross-sectional study published in Frontiers in Clinical Diabetes and Healthcare assessed the prevalence of ACD among 232 children and adolescents with type 1 diabetes mellitus (T1DM) receiving care at the Dubai Diabetes Center between January 2020 and January 2023.

Among all participants, 87% were using continuous glucose monitoring (CGM) systems. Documented ACD occurred in 7.92% of users (95% CI: 4.6–12.54), with a higher prevalence in females (9.37%) than in males (6.6%). Statistical analysis found no significant correlation between CGM use and ACD incidence (p = 0.581).

The study highlights the importance of dermatologic vigilance in diabetes technology use. Biomedical manufacturers are encouraged to disclose adhesive constituents and develop safer alternatives. Increased clinician awareness of skin barrier integrity and hypersensitivity reactions can improve adherence, comfort, and glycemic management in young individuals with T1DM.